

May 15, 2026

To,
Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street,
Mumbai - 400001
Script Code - 540737

Sub: Press Release

With reference to the captioned subject, we enclose herewith the Press Release with respect to Audited Financial Results of the Company for the quarter and year ended March 31, 2026.

Kindly take the same on your record.

Thanking You,

**Yours faithfully,
For Shree Ganesh Remedies Limited**

**Aditya Patel
Company Secretary**

Enc. a/a



Head Office :
Plot No. 6011, 6012, 6002 & 6003,
GIDC Estate, Ankleshwar - 393 002,
Gujarat (INDIA)
Ph.: +91 9614961469, 7574976076
CIN No. : L24230GJ1995PLC025661

(Unit-2) :
Plot No. 6714/2,-6715 GIDC Estate,
Ankleshwar - 393 002, Gujarat (INDIA)
Ph.: +91 9614961469, 7574976076
GSTIN : 24ABACS1471R1ZQ (Zero)



www.ganeshremedies.com
WEBSITE
contact@ganeshremedies.com |
EMAIL

SHREE GANESH REMEDIES LIMITED REPORTS Q4 & FY26 RESULTS

Ankleshwar, May 14th, 2026: Shree Ganesh Remedies Limited, one of the fastest growing CMO & CDMO based in India for Pharmaceutical Intermediates & Fine Chemicals, announced its financial results for Q4 & FY26.

Commenting on the results, Mr. Gunjan Kothia, Promoter said:

As guided through the course of the year, FY26 was envisaged as a year of consolidation for the Company, and the results of the year reflect that. Whilst the headline financial performance does not show significant growth, the business has become structurally and fundamentally stronger, and is now well placed for healthy growth in the years ahead.

We have utilised the year gone by to deepen the foundations of the business, securing critical approvals, advancing work on newer and more innovative molecules, and meaningfully building up both our capabilities and capacities.

I am please to report that we are making strong progress on our CRAMS engagements across agrochemicals, pharmaceuticals and electronic applications, with active projects spanning Europe and Japan. We have achieved significant milestones on these mandates, and I am delighted to share that the pilot trials for these projects have been successfully completed during Q4FY26. We will now move into the commercial trial phase, and subject to the requisite customer and regulatory approvals, we expect to commence commercial production of these molecules thereafter.

This represents an important inflection point for our specialty and contract manufacturing platform. On the capacity front, our Block 7 expansion programme remains firmly on track, and we now expect commercial production to commence from Q2FY27. This additional capacity is being purposefully built to support our pipeline of niche, application-led molecules and will play a meaningful role in driving the next phase of growth.

The broader operating environment has, admittedly, continued to remain challenging. The slowdown in Europe has persisted, the ongoing war situation has introduced further uncertainty, raw material markets have witnessed considerable volatility, and a number of customers have deferred purchases amidst this backdrop. Against these headwinds, I believe our performance reflects a measure of resilience. We have remained steadfast in our strategic focus on building a robust platform, concentrating on niche applications where competitive intensity is limited and where the runway for differentiated growth is meaningful. Whilst this path may appear measured in pace, we firmly believe it is the right approach to create a more sustainable and profitable business over the long term.

Looking ahead, we remain confident and well prepared to deliver improving growth and profitability in the coming years. With the pilot facility now fully operational, Block 7 nearing commissioning, our CRAMS projects moving from pilot to commercial stage, and a stronger product development pipeline, the Company is poised for growth.

Financial Highlights for Quarter Ended March 31st, 2026:

(₹ In crore & %)

REVENUE
33.20 Cr.
⬆️ 36% YoY

EBITDA
11.37 Cr.
⬆️ 15% YoY

PAT
6.27 Cr.
⬇️ -5% YoY

EBITDA MARGINS
34.3 %
⬇️ -616 BPS YoY

19.72 Cr.
Revenue from Pharma Intermediates in Q4FY26

13.47 Cr.
Revenue from Speciality Chemicals in Q4FY26

25.14 Cr.
Revenue from Exports in Q4FY26

8.05 Cr.
Revenue from Domestic Sales in Q4FY26

Financial Highlights for Year Ended December 31st, 2026:

(₹ In crore & %)

REVENUE
109.29 Cr.
⬆️ 1% YoY

EBITDA
35.02 Cr.
⬇️ -11% YoY

PAT
17.77 Cr.
⬇️ -23% YoY

EBITDA MARGINS
32.0 %
⬇️ -406 BPS YoY

68.81 Cr.
Revenue from Pharma Intermediates in FY26

40.47 Cr.
Revenue from Speciality Chemicals in FY26

63.10 Cr.
Revenue from Exports in FY26

46.18 Cr.
Revenue from Domestic Sales in FY26

Financial Highlights:

PARTICULARS (₹ IN CRORES)	Q4FY25	Q3FY26	Q4FY26	YoY Change	QoQ Change	FY25	FY26	YoY Change
Revenue from Operations	24.43	21.11	33.20	36%	57%	108.60	109.29	1%
Total Income	26.72	21.76	34.22	28%	57%	112.33	112.32	0%
Operating Expenses	14.55	14.38	21.82	50%	52%	69.38	74.27	7%
EBITDA (Excluding OI & EI)	9.88	6.73	11.37	15%	69%	39.21	35.02	-11%
EBITDA %	40.4%	31.9%	34.3%	-616 bps	238 bps	36.1%	32.0%	406 bps
Finance Cost	0.96	0.74	0.88	-9%	19%	2.08	3.56	71%
Depreciation & Ammortization	2.42	2.67	2.80	15%	5%	9.57	10.47	9%
PBT	8.78	3.98	8.72	-1%	119%	31.30	24.01	-23%
PAT	6.60	3.10	6.27	-5%	103%	23.10	17.77	-23%
EPS (₹)	5.13	2.41	4.88	-5%	102%	17.98	13.84	-23%

About Shree Ganesh Remedies Limited: (SGRL)

Shree Ganesh Remedies Limited is a leading player in the chemical manufacturing industry, specialising in pharmaceutical intermediates and specialty chemicals. With over 19 years of excellence, the company is renowned for its unparalleled expertise in advanced chemical synthesis and complex chemical reactions. Strategically expanding its operations, Shree Ganesh Remedies is focused on innovation through strategic R&D investments and state-of-the-art infrastructure. The company serves over 20 countries, including key markets in the EU and the US, offering tailored solutions to global industry leaders. Committed to sustainable practices, Shree Ganesh Remedies holds multiple accreditations, including ISO certifications and EcoVadis Bronze. With ongoing expansions at its Ankleshwar and Dahej sites and a strategic shift towards complex niche specialty chemicals, the company is well-positioned for future growth and continues to deliver high-quality, custom manufacturing solutions to its clients.

Contact us:

Aditya Patel
Company Secretary
Shree Ganesh Remedies Limited
Email: investors@ganeshremedies.com

Abhishek Mehra
Investor Relations Advisors
TIL Advisors Private Limited
Email: abhishek@theinvestmentlab.in
Mobile No.: +91 95588 14500

Certain statements in this document that are not historical facts are forward looking statements. Such forward looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward- looking statements. Shree Ganesh Remedies Limited will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.